GLP-1 adjacent compounds sit under extra scrutiny even inside an already-restricted category. Here's how semaglutide and tirzepatide campaigns need to be built differently.
Semaglutide and tirzepatide occupy a stricter compliance tier than most peptide compounds, simply because of how visible and heavily searched the GLP-1 category has become. Google's review systems apply extra scrutiny here specifically because the volume of both legitimate and non-compliant advertisers in this space has grown fast enough to draw dedicated policy attention. Treating a GLP-1 adjacent campaign the same way you'd treat a lower-profile compound is one of the more common mistakes we see.
Semaglutide and tirzepatide are FDA-approved as prescription medications under specific brand names for specific indications. Research-grade or compounded versions marketed under the generic compound name sit in a different regulatory position, and Google's automated systems are tuned to catch advertisers who blur that line, intentionally or not, given how much consumer search volume and enforcement attention this specific category attracts compared to less mainstream peptides.
| Area | Standard Peptide Approach | GLP-1 Adjacent Approach |
| Keyword selection | Compound name plus research-use modifiers | Same, plus active exclusion of brand-name drug terms and dosing-comparison queries |
| Ad copy | Research-use framing sufficient | Research-use framing plus explicit avoidance of weight-loss outcome claims |
| Landing pages | Standard compliance disclosures | Additional disclosures distinguishing the product from prescription GLP-1 medications |
| Review frequency | Standard monitoring cadence | More frequent self-audits given the category's higher enforcement activity |
The strongest-performing GLP-1 adjacent landing pages we've built distinguish the product clearly and early: what it is, what it's sold for, and what it is explicitly not being marketed as. This isn't just a policy checkbox, it's also what separates pages that survive periodic re-review from pages that get flagged again a few months after initial approval.
Given the extra scrutiny on this specific sub-category, LegitScript certification and Google's Restricted Drug Terms Certification carry more practical weight here than for lower-profile compounds. We cover the certification process in detail in our LegitScript certification guide, worth prioritising if GLP-1 adjacent products make up a meaningful share of your catalog.
GLP-1 adjacent compounds aren't unadvertisable, but they need a stricter version of the same compliance discipline that works for other peptides: tighter keyword exclusions, more explicit landing page framing, and more frequent self-review. Brands that apply standard peptide-category compliance to this specific sub-category are more likely to get flagged, not less, given how much enforcement attention it draws.
We'll review your current keyword list, ad copy, and landing pages specifically against the stricter standard this category requires.
Or email directly: sveta@oney.studio
Oney Studio is a specialist Google Ads agency for peptide and research chemical brands. We build compliance-first account architecture that scales, from cold start to six-figure monthly revenue, without account-level policy flags.
Get a free 30-minute audit of your Google Ads or Meta Ads account. We’ll review compliance, structure, and growth opportunities — no strings attached.
Book a Free Audit